Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML

Gilead Sciences, Inc. announced that the US FDA has placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab to treat AML. The FDA action follows the previously announced discontinuation of the Phase III ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes.